All News

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

The AAP acknowledges challenges for families but emphasizes mandatory vaccination as crucial for safe school environments.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

Your daily dose of the clinical news you may have missed.

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.

Your daily dose of the clinical news you may have missed.

Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.

Your daily dose of the clinical news you may have missed.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.